Charles River Laboratories CEO Birgit Girshick was featured in The Pharma Letter discussing the company's strategy to reaccelerate growth through regulated safety assessment, data-sharing, and new approach methodologies.
Public source
Publisher name
Public post
Our CEO, Birgit Girshick, was featured in The Pharma Letter, where she discussed Charles River’s strategy to reaccelerate growth through a sharper focus on regulated saf…
Company
Charles River Laboratories
Together, We Create Healthier Lives
- Industry
- Biotechnology Research
- Location
- Wilmington, US
- Company size
- 10,001+ employees
About Charles River Laboratories
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
See moreLatest activity
Latest activity from Charles River Laboratories
47 signals
Products & Services
Charles River Laboratories released a fully automated cartridge production suite for bacterial endotoxin testing to drive greater quality, efficiency, traceability, and scalability.
People
Charles River Laboratories welcomed interns like Nokutenda Chelsea Choto to gain hands-on experience while discovering the people, culture, and sense of community that make Charles River special.
Research & Knowledge
Charles River Laboratories launched The DART Board, a new EurekaBlog series spotlighting topics in developmental and reproductive toxicology, including the inaugural article Why Every Ovarian Follicle Count Matters.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Axolabs
Axolabs CEO Susanne Leonhartsberger shared her perspective on the opportunities shaping the future of the oligonucleotide market and how Axolabs supports customers from discovery through to commercial supply in an interview with PharmaBoardroom.
Presence & Recognition
Scantox Group
Scantox Group announced that Matt Tate will be one of four expert speakers in Session CE7 of the ACT 2026 Continued Education Course focused on Genetic Toxicology in Drug Development.
Presence & Recognition
Evotec
Evotec experts discuss a holistic approach to de-risking and development built on horizontal and vertical integration on 7th of September.
Presence & Recognition
FUJIFILM Cellular Dynamics, Inc
FUJIFILM Cellular Dynamics, Inc employee Nina Bauer, PhD MBA, EVP, Strategy and Commercial, participated in an interview with Drug Discovery News discussing how iPSCs are advancing toxicity testing, high-throughput screening, organoid development, and advanced therapies.
Presence & Recognition
Eurofins US Food, Feed, & Supplement Testing